Sumanta Mondal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sumanta Mondal has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Koustav Dutta
Department of Pharmaceutical Chemistry, School of Pharmacy, GITAM (Deemed to Be University), Visakhapatnam, India
2 shared publicationsNaresh Panigrahi
2 shared publicationsPartha Roy
2 shared publicationsAishik Banerjee
1 shared publication- Aishik Banerjee
GITAM (Deemed to be University), Visakhapatnam, India
1 shared publication Amartya Nandi
1 shared publication
Latest Publications
- 1 December 2026
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 27 (10) , 887-903
Valorization of Keratin-Rich Waste: Extraction, Characterization, and Biomedical Applications
Keratin is a fibrous structural protein that occurs in abundance in hair, wool, feathers, horns, and nails, and it is a valuable biopolymer with great biomedical applications. The poultry, textile, and leather industries produce millions of tons of keratin waste annually, resulting in significant environmental problems due to their negligible biodegradability as well as the lack of environmentally friendly disposal methods. Recent studies have moved towards valorizing keratin waste, where ongoing research in extraction, purification, and modification techniques has made its applications viable in wound healing, tissue engineering, drug delivery, cosmetics, and ecological remediation. In contrast to previous reviews, this article presents a critical evaluation of traditional, chemical, and industrial extraction methods, focusing on their efficiency, scalability, and sustainability. This study also emphasizes biomedical applications, addresses the challenges and bottlenecks like immunogenicity, reproducibility, and regulatory hurdles, and charts future research agendas for the development of keratin-based biomaterials within a circular bioeconomy scenario. Thus, this review closes the gap between keratin waste management and biomedical innovation and provides novel insights toward sustainable exploitation and next-generation therapeutic applications.
- 1 December 2026
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 27 (10) , 887-903
Valorization of Keratin-Rich Waste: Extraction, Characterization, and Biomedical Applications
Keratin is a fibrous structural protein that occurs in abundance in hair, wool, feathers, horns, and nails, and it is a valuable biopolymer with great biomedical applications. The poultry, textile, and leather industries produce millions of tons of keratin waste annually, resulting in significant environmental problems due to their negligible biodegradability as well as the lack of environmentally friendly disposal methods. Recent studies have moved towards valorizing keratin waste, where ongoing research in extraction, purification, and modification techniques has made its applications viable in wound healing, tissue engineering, drug delivery, cosmetics, and ecological remediation. In contrast to previous reviews, this article presents a critical evaluation of traditional, chemical, and industrial extraction methods, focusing on their efficiency, scalability, and sustainability. This study also emphasizes biomedical applications, addresses the challenges and bottlenecks like immunogenicity, reproducibility, and regulatory hurdles, and charts future research agendas for the development of keratin-based biomaterials within a circular bioeconomy scenario. Thus, this review closes the gap between keratin waste management and biomedical innovation and provides novel insights toward sustainable exploitation and next-generation therapeutic applications.
- Open Access
- 12 August 2026
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 12 (1) , 81
Analytical method development, validation for the estimation of brivaracetam in bulk drug substance by RP-HPLC and identification of its major degradation product: a quality by design approach
Background: The research involved a systematic and proactive approach, integrating quality considerations throughout the product lifecycle, from initial conception to final production. A design space was established by thoroughly examining these relationships, ensuring the product consistently meets desired quality standards. Objective: This study employed an approach of Quality by Design (AQbD) strategy for developing and validating stability-indicating method for the estimation of brivaracetam in bulk drug substance via RP-HPLC, including characterizing its major degradation products. Methods: The analytical separation was performed using a Waters Alliance HPLC system, equipped with an X-Terra RP18 column (250 × 4.6 mm, 5 µm), and a gradient elution technique with mobile phases A (0.1% w/v perchloric acid in water) and B (water: acetonitrile, 10:90, v/v) at a flow rate of 1.2 mL/min, resulting in a retention time of about 16.8 min. Results: The major degradation product was identified as (S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanoic acid, with a retention time of 23.6 min, significantly different from brivaracetam. The percentage of degradation in acid conditions was found to be 10%. The method demonstrated high accuracy, with recovery rates between 99.7% and 100.4%. The %RSD value for the method and intermediate precision was 0.2% and 0.3%, respectively. Conclusions: The Approach Quality by Design (AQbD) methodology enabled a comprehensive understanding of the factors influencing chromatographic separation, enhancing assurance in the established HPLC method’s capacity to fulfill its intended objectives.
- 12 August 2026
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 12 (1) , 81
Open AccessAnalytical method development, validation for the estimation of brivaracetam in bulk drug substance by RP-HPLC and identification of its major degradation product: a quality by design approach
Background: The research involved a systematic and proactive approach, integrating quality considerations throughout the product lifecycle, from initial conception to final production. A design space was established by thoroughly examining these relationships, ensuring the product consistently meets desired quality standards. Objective: This study employed an approach of Quality by Design (AQbD) strategy for developing and validating stability-indicating method for the estimation of brivaracetam in bulk drug substance via RP-HPLC, including characterizing its major degradation products. Methods: The analytical separation was performed using a Waters Alliance HPLC system, equipped with an X-Terra RP18 column (250 × 4.6 mm, 5 µm), and a gradient elution technique with mobile phases A (0.1% w/v perchloric acid in water) and B (water: acetonitrile, 10:90, v/v) at a flow rate of 1.2 mL/min, resulting in a retention time of about 16.8 min. Results: The major degradation product was identified as (S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanoic acid, with a retention time of 23.6 min, significantly different from brivaracetam. The percentage of degradation in acid conditions was found to be 10%. The method demonstrated high accuracy, with recovery rates between 99.7% and 100.4%. The %RSD value for the method and intermediate precision was 0.2% and 0.3%, respectively. Conclusions: The Approach Quality by Design (AQbD) methodology enabled a comprehensive understanding of the factors influencing chromatographic separation, enhancing assurance in the established HPLC method’s capacity to fulfill its intended objectives.
- 30 September 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 20 (5) , 1-23
Pharmacognostic, Phytochemical, and Multi-Analytical Profiling of the Leaves and Fruit of Terminalia Catappa L Integrated with In-Silico Docking Studies
- 30 September 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 20 (5) , 1-23
Pharmacognostic, Phytochemical, and Multi-Analytical Profiling of the Leaves and Fruit of Terminalia Catappa L Integrated with In-Silico Docking Studies
- Open Access
- 1 July 2025
- Published by Wolters Kluwer Health in Journal of Pharmacy and Bioallied Sciences
- Vol. 17 (3) , 134-139
Identification of Degradation Products and a Stability-Indicating RP-HPLC Method for the Determination of Belzutifan in Pharmaceutical Dosage Forms
Background: Hypoxia-inducible factor-2alpha (HIF-2α) is a protein, the selective inhibitor of which (belzutifan) is used in the treatment of cancers related to von Hippel-Lindau (VHL) disease. No analytical procedure has been so far reported in the identification of forced degradation products of belzutifan. Thus, the current project was conducted to design and approve the liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) technique to perform a full analysis of it. Objective: This research was to develop and confirm a strong high-performance liquid chromatography (HPLC) procedure in the quantification of belzutifan in the tablet dosage form and to utilize LC-MS/MS in the characterization of the forced degradation products of belzutifan. Approach: The separation was done by the chromatographic method utilizing a Zorbax C 18 column with the mobile phase comprised of acetonitrile and 0.1% formic acid (50:50, v/v), and the flow rate was 1.0 mL/min with 247nm as a detector wavelength. Belzutifan had a retention time of 2.338 min and a total reaction time of 4 min. Results: The derived technique showed great linearity (R2 > 0.999) in the range of concentrations (10-60 μg/ml) and good accuracy, precision, and strength. The forced degradation analysis identified specific degradation products, which were further identified using the LC-MS/MS, thus gathering significant information about the stability profile of belzutifan in stressful environments. Conclusion: This study developed and validated a simple, rapid, cost-effective, and highly sensitive RP-HPLC method for quantitative estimation of belzutifan in tablets. The method complied with ICH guidelines, demonstrating excellent linearity, accuracy, specificity, robustness, and stability. Linearity was achieved over a wide range, with no interference from excipients, confirming its reliability. Relative standard deviations (RSD) were below 2%, indicating precision and reproducibility. Owing to its simplicity and efficiency, the method is suitable for routine quality control in pharmaceutical laboratories.
- 1 July 2025
- Published by Wolters Kluwer Health in Journal of Pharmacy and Bioallied Sciences
- Vol. 17 (3) , 134-139
Open AccessIdentification of Degradation Products and a Stability-Indicating RP-HPLC Method for the Determination of Belzutifan in Pharmaceutical Dosage Forms
Background: Hypoxia-inducible factor-2alpha (HIF-2α) is a protein, the selective inhibitor of which (belzutifan) is used in the treatment of cancers related to von Hippel-Lindau (VHL) disease. No analytical procedure has been so far reported in the identification of forced degradation products of belzutifan. Thus, the current project was conducted to design and approve the liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) technique to perform a full analysis of it. Objective: This research was to develop and confirm a strong high-performance liquid chromatography (HPLC) procedure in the quantification of belzutifan in the tablet dosage form and to utilize LC-MS/MS in the characterization of the forced degradation products of belzutifan. Approach: The separation was done by the chromatographic method utilizing a Zorbax C 18 column with the mobile phase comprised of acetonitrile and 0.1% formic acid (50:50, v/v), and the flow rate was 1.0 mL/min with 247nm as a detector wavelength. Belzutifan had a retention time of 2.338 min and a total reaction time of 4 min. Results: The derived technique showed great linearity (R2 > 0.999) in the range of concentrations (10-60 μg/ml) and good accuracy, precision, and strength. The forced degradation analysis identified specific degradation products, which were further identified using the LC-MS/MS, thus gathering significant information about the stability profile of belzutifan in stressful environments. Conclusion: This study developed and validated a simple, rapid, cost-effective, and highly sensitive RP-HPLC method for quantitative estimation of belzutifan in tablets. The method complied with ICH guidelines, demonstrating excellent linearity, accuracy, specificity, robustness, and stability. Linearity was achieved over a wide range, with no interference from excipients, confirming its reliability. Relative standard deviations (RSD) were below 2%, indicating precision and reproducibility. Owing to its simplicity and efficiency, the method is suitable for routine quality control in pharmaceutical laboratories.
- Open Access
- 25 June 2025
- Published by Manuscript Technomedia LLP in Pharmacognosy Research
- Vol. 17 (3) , 740-754
Aflatoxin: A Prevalent Toxin in the Demesne of Existence
Aflatoxin, a mycotoxin origin from food-borne microbes, poses a significant and remarkable risk to the safety and integrity of food. Mycotoxin-producing fungi can infect goods intended for human and animal consumption, impacting both populations. Among mycotoxins, aflatoxin B 1 harms many living organisms, including microorganisms, plants, laboratories, pet animals, and cultured cells. Aflatoxins are incredibly liposoluble and easily absorbed from the exposure site, typically entering the bloodstream through the respiratory and gastrointestinal systems. In humans and animals, the reactive form of aflatoxin, AFB 1 , is metabolized through cytochrome P450 microsomal enzymes into aflatoxins-8,9-epoxide, which then binds with DNA and albumins present in blood serum, forming an active-adducts that damage DNA. Aflatoxins are the well-researched class of mycotoxins, with clear correlations to carcinogenic, hepatotoxic, mutagenic, and teratogenic effects. Therefore, aflatoxin detection is crucial for maintaining food safety and public health, as mycotoxins can withstand high temperatures during storage and cooking. Several analytical and chemical methods can detect, identify, and control aflatoxin contamination with precision, contributing to food safety and public health. Further worldwide research is crucial to deepen our understanding of toxic pollutants, toxicity patterns, regulatory mechanisms, and decontamination strategies, as preventing aflatoxin contamination needs adequate funding and collaboration.
- 25 June 2025
- Published by Manuscript Technomedia LLP in Pharmacognosy Research
- Vol. 17 (3) , 740-754
Open AccessAflatoxin: A Prevalent Toxin in the Demesne of Existence
Aflatoxin, a mycotoxin origin from food-borne microbes, poses a significant and remarkable risk to the safety and integrity of food. Mycotoxin-producing fungi can infect goods intended for human and animal consumption, impacting both populations. Among mycotoxins, aflatoxin B 1 harms many living organisms, including microorganisms, plants, laboratories, pet animals, and cultured cells. Aflatoxins are incredibly liposoluble and easily absorbed from the exposure site, typically entering the bloodstream through the respiratory and gastrointestinal systems. In humans and animals, the reactive form of aflatoxin, AFB 1 , is metabolized through cytochrome P450 microsomal enzymes into aflatoxins-8,9-epoxide, which then binds with DNA and albumins present in blood serum, forming an active-adducts that damage DNA. Aflatoxins are the well-researched class of mycotoxins, with clear correlations to carcinogenic, hepatotoxic, mutagenic, and teratogenic effects. Therefore, aflatoxin detection is crucial for maintaining food safety and public health, as mycotoxins can withstand high temperatures during storage and cooking. Several analytical and chemical methods can detect, identify, and control aflatoxin contamination with precision, contributing to food safety and public health. Further worldwide research is crucial to deepen our understanding of toxic pollutants, toxicity patterns, regulatory mechanisms, and decontamination strategies, as preventing aflatoxin contamination needs adequate funding and collaboration.
- Open Access
- 7 March 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 204-224
COMPUTATIONAL MULTI-FACTOR MODELING TO THE SIMULTANEOUS DETERMINATION OF ASSAY AND RELATED SUBSTANCES METHOD DEVELOPMENT, VALIDATION, AND IDENTIFICATION OF MAJOR DEGRADATION PRODUCT OF COVID-19 DRUG MOLNUPIRAVIR BY HPLC: A STRATEGIC RESEARCH USING AQBD
Objective: In the current study, a new approach was developed for the simultaneous determination of molnupiravir with its degradation products using RP-HPLC by following the Analytical Quality by Design (AQbD) approach, a proactive strategy for advancing pharmaceutical research. Methods: Development was carried out by applying the two levels of fractional factorial design (2[5-1] with Resolution: V, four center points, and no replicates) to the five independent factors. The separation was achieved using liquid chromatography, equipped with XBridge BEH Shield (250 mm x 4.6 mm, 3.5 µm) RP18 column at 260 nm with gradient elution. A force degradation study was performed in different stressed conditions and a major degradant was identified using modern analytical techniques. Results: The dependent factors were assessed against independent factors using the H-N plot, Pareto chart, and 3D surface plot applied through ANOVA. Major degradant obtained from stress study was identified and characterized using LC-MS, NMR, and FTIR techniques. The analytical method was found to be specific, precise (% RSD ≤ 2.0), linear (r = 0.9999) and accurate (99.2-101.4 %) with a 0.2-0.6 mg/ml range. The LOD and LOQ were 0.02 % (0.08 µg/ml, S/N ratio ≥ 3) and 0.05 % (0.2 µg/ml, S/N ratio ≥ 10, % RSD: 2.2) respectively. The analytical solutions were stable for 48 hour in the clear glassware at room temperature. The study depicts the successful development and validation of a simultaneous determination of assay and related substances by RP-HPLC using Design of Experiments (DoE) approach. Conclusion: A Fractional Factorial Design (FFD) experiment explored the interactions of dependent with independent factors using Design Expert software, version 13.0. This AQbD-driven approach provided an in-depth understanding of chromatographic separation factors, ensuring method reliability and effectiveness for simultaneously determining the purity and impurity of molnupiravir, assisting in regulatory compliance.
- 7 March 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 204-224
Open AccessCOMPUTATIONAL MULTI-FACTOR MODELING TO THE SIMULTANEOUS DETERMINATION OF ASSAY AND RELATED SUBSTANCES METHOD DEVELOPMENT, VALIDATION, AND IDENTIFICATION OF MAJOR DEGRADATION PRODUCT OF COVID-19 DRUG MOLNUPIRAVIR BY HPLC: A STRATEGIC RESEARCH USING AQBD
Objective: In the current study, a new approach was developed for the simultaneous determination of molnupiravir with its degradation products using RP-HPLC by following the Analytical Quality by Design (AQbD) approach, a proactive strategy for advancing pharmaceutical research. Methods: Development was carried out by applying the two levels of fractional factorial design (2[5-1] with Resolution: V, four center points, and no replicates) to the five independent factors. The separation was achieved using liquid chromatography, equipped with XBridge BEH Shield (250 mm x 4.6 mm, 3.5 µm) RP18 column at 260 nm with gradient elution. A force degradation study was performed in different stressed conditions and a major degradant was identified using modern analytical techniques. Results: The dependent factors were assessed against independent factors using the H-N plot, Pareto chart, and 3D surface plot applied through ANOVA. Major degradant obtained from stress study was identified and characterized using LC-MS, NMR, and FTIR techniques. The analytical method was found to be specific, precise (% RSD ≤ 2.0), linear (r = 0.9999) and accurate (99.2-101.4 %) with a 0.2-0.6 mg/ml range. The LOD and LOQ were 0.02 % (0.08 µg/ml, S/N ratio ≥ 3) and 0.05 % (0.2 µg/ml, S/N ratio ≥ 10, % RSD: 2.2) respectively. The analytical solutions were stable for 48 hour in the clear glassware at room temperature. The study depicts the successful development and validation of a simultaneous determination of assay and related substances by RP-HPLC using Design of Experiments (DoE) approach. Conclusion: A Fractional Factorial Design (FFD) experiment explored the interactions of dependent with independent factors using Design Expert software, version 13.0. This AQbD-driven approach provided an in-depth understanding of chromatographic separation factors, ensuring method reliability and effectiveness for simultaneously determining the purity and impurity of molnupiravir, assisting in regulatory compliance.
- Open Access
- 12 February 2025
- Published by Manuscript Technomedia LLP in International Journal of Pharmaceutical Investigation
- Vol. 15 (2) , 388-396
Determination of Momelotinib in Rat Plasma by LC-MS/MS: Application to Pharmacokinetics Study
Objectives This study describes developing and validating a novel method using LC-MS/ MS to measure the concentration of Momelotinib in rat plasma.Materials and Methods The pharmacokinetic applicability of the process was assessed in rats using a Symmetry C18 column (250 mmx4.6 mm, 5 µm) at room temperature for separation. The mobile phase consisted of a mixture of acetonitrile and 0.1% formic acid (45:55) with a 1.0 mL/min flow rate and an injection volume of 10 µL. The Liquid Chromatography (LC) process was carried out over 5 min, with the mass spectrometer operating in positive ESI mode. The mass-to-charge ratio transitions for Momelotinib and Oclacitinib were determined as m/z 415.4285→160.4698 and 338.2142→266.9137, respectively.Results and Discussion The concentration range for Momelotinib was established at 7.50-60.00 ng/mL, with a correlation coefficient of 0.9999. The precision and accuracy for High-Quality Control (HQC), Medium-Quality Control (MQC), Low-Quality Control (LQC) and Lower Limit of Quantification (LLQC) were 97.52%, 98.97%, 95.46% and 92.55%, respectively. The recovery accuracy for Momelotinib was found to be 97.29%. In pharmacokinetic studies, Momelotinib exhibited an average AUC0-t of 156 ng-hr/mL and a Cmax of 27.2 ng/mL in rats.Conclusion In conclusion, this validated approach effectively demonstrates the determination of pharmacokinetic parameters following the oral administration of Momelotinib in Wistar rats.
- 12 February 2025
- Published by Manuscript Technomedia LLP in International Journal of Pharmaceutical Investigation
- Vol. 15 (2) , 388-396
Open AccessDetermination of Momelotinib in Rat Plasma by LC-MS/MS: Application to Pharmacokinetics Study
Objectives This study describes developing and validating a novel method using LC-MS/ MS to measure the concentration of Momelotinib in rat plasma.Materials and Methods The pharmacokinetic applicability of the process was assessed in rats using a Symmetry C18 column (250 mmx4.6 mm, 5 µm) at room temperature for separation. The mobile phase consisted of a mixture of acetonitrile and 0.1% formic acid (45:55) with a 1.0 mL/min flow rate and an injection volume of 10 µL. The Liquid Chromatography (LC) process was carried out over 5 min, with the mass spectrometer operating in positive ESI mode. The mass-to-charge ratio transitions for Momelotinib and Oclacitinib were determined as m/z 415.4285→160.4698 and 338.2142→266.9137, respectively.Results and Discussion The concentration range for Momelotinib was established at 7.50-60.00 ng/mL, with a correlation coefficient of 0.9999. The precision and accuracy for High-Quality Control (HQC), Medium-Quality Control (MQC), Low-Quality Control (LQC) and Lower Limit of Quantification (LLQC) were 97.52%, 98.97%, 95.46% and 92.55%, respectively. The recovery accuracy for Momelotinib was found to be 97.29%. In pharmacokinetic studies, Momelotinib exhibited an average AUC0-t of 156 ng-hr/mL and a Cmax of 27.2 ng/mL in rats.Conclusion In conclusion, this validated approach effectively demonstrates the determination of pharmacokinetic parameters following the oral administration of Momelotinib in Wistar rats.
- Open Access
- 13 December 2024
- Published by Bentham Science Publishers Ltd. in Current Indian Science
- Vol. 02 (1) , 1-14
“Punarnava” (Boerhaavia diffusa) : An Ancient Herbal Medicine with the Emphasis of Ayurveda on its Therapeutic Potential
A broad name for plant compounds with various structures and functions is “phytochemical.” When ingested by humans, phytochemicals may have biological activity. Plant foods, such as fruits, vegetables, whole grains, nuts, and seeds are the most prevalent sources of phytochemicals. Boerhaavia diffusa L. nom. cons. is a perennial creeping herb that grows throughout India. In the Indian medical system, it is generally referred to as “Punarnava”. In some areas of India, it is frequently used to treat jaundice. According to Ayurveda, B. diffusa is categorized as a “Rasayana” herb, which is believed to have anti-aging, disease-prevention, and life-strengthening properties. These properties are thought to significantly impact the global disease burden and the cost and accessibility of healthcare. This one is one of the first Eastern remedies that Ayurveda mentions as a possible treatment for several illnesses. Numerous ethnopharmacological reports highlight its involvement in reproductive, gastrointestinal, respiratory, urinary, hepatic/jaundice, cardiovascular, and cancer problems. Beyond that, because of the plant's therapeutic value derived from flavonoids and polyphenols, physicians and scientists should take more significant advantage of this plant to learn more about its biological and therapeutic qualities. Its taxonomy and geographic description, ethnobotanical insights, and various pharmacological characteristics were the main topics of this paper.
- 13 December 2024
- Published by Bentham Science Publishers Ltd. in Current Indian Science
- Vol. 02 (1) , 1-14
Open Access“Punarnava” (Boerhaavia diffusa) : An Ancient Herbal Medicine with the Emphasis of Ayurveda on its Therapeutic Potential
A broad name for plant compounds with various structures and functions is “phytochemical.” When ingested by humans, phytochemicals may have biological activity. Plant foods, such as fruits, vegetables, whole grains, nuts, and seeds are the most prevalent sources of phytochemicals. Boerhaavia diffusa L. nom. cons. is a perennial creeping herb that grows throughout India. In the Indian medical system, it is generally referred to as “Punarnava”. In some areas of India, it is frequently used to treat jaundice. According to Ayurveda, B. diffusa is categorized as a “Rasayana” herb, which is believed to have anti-aging, disease-prevention, and life-strengthening properties. These properties are thought to significantly impact the global disease burden and the cost and accessibility of healthcare. This one is one of the first Eastern remedies that Ayurveda mentions as a possible treatment for several illnesses. Numerous ethnopharmacological reports highlight its involvement in reproductive, gastrointestinal, respiratory, urinary, hepatic/jaundice, cardiovascular, and cancer problems. Beyond that, because of the plant's therapeutic value derived from flavonoids and polyphenols, physicians and scientists should take more significant advantage of this plant to learn more about its biological and therapeutic qualities. Its taxonomy and geographic description, ethnobotanical insights, and various pharmacological characteristics were the main topics of this paper.